Quantisnow Logo
Dashboard

Director Ragard John Phillip converted options into 4,843 shares, increasing direct ownership by 4% to 129,890 units (SEC Form 4)

$AWH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Get the next $AWH alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Get startedLearn more

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

Get startedLearn more
App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $AWH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AWH

DatePrice TargetRatingAnalyst
1/12/2022$4.00Overweight
Cantor Fitzgerald
More analyst ratings

$AWH
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

    Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations.Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and life science tools domains, working for start-up, scale-up, and established businesses. He brings hands-on leadership experience in clinical diagnostics specializing in precision medicine and patient outcomes in oncology, rare dise

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

  • Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

    AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

  • Aspira Women's Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award

    AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the first development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result, Aspira has received a $2 million cash payment under the terms of the related agreement. ARPA-H's Sprint for Women's Health was created to address critical unmet challenges in women's health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women. As previously a

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$AWH
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AWH
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$AWH
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AWH
 SEC Filings

See more

$AWH
 Leadership Updates

Live Leadership Updates

See more

  • Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

    AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

  • Aspira Women's Health Selected as a Spoke for the Investor Catalyst Hub

    AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

  • Aspira Women's Health Appoints Mr. John Ragard to its Board of Directors

    AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mr. John Ragard to its Board of Directors. Mr. Ragard is an accomplished executive with extensive experience successfully managing several billion-dollar portfolios over his career. "We are pleased to welcome John to our Board of Directors," said Ms. Jannie Herchuk, Chairwoman of the Board at Aspira Women's Health. "John brings a wealth of experience and a keen understanding of Wall Street, having been a successful money manager for the past

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$AWH
 Financials

Live finance-specific insights

See more

  • Aspira Women's Health Reports Selected Third Quarter 2024 Financial Results

    Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported selected financial results for the third quarter ended September 30, 2024. "OvaWatch® product volume, which we believe is the most import

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

  • Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024

    AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Details of the call are as follows: Conference Call & Webcast Details:Date:Thursday, November 14, 2024Time:8:30 am ETToll Free:877-545-0320International:973-528-0002Access Code:436613Webcast:R

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

  • Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12

    AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30, 2024, on Monday, August 12, 2024. Management will also host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date: Monday, August 12, 2024Time: 4:30 p.m. ETToll Free:877-407-4018Webcast:Click HERE   A replay of the webcast will also be

    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$AWH
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more